Propanc Biopharma, Inc. Common Stock (PPCB : NASDAQ)
Common Stock
$0.28
USD
+0.01 (2.19%)
Last updated: 2026-10-23
Follow PPCB
PPCB
Propanc Biopharma, Inc. Common Stock
WealthAwesomePerformance
1 Day
+921.90%
1 Week
+718.71%
1 Month
+345.86%
YTD
+63.74%
Key Statistics
Market Cap
$289,271
52W High
$2.80
52W Low
$0.00
P/E Ratio
-
50 Day MA
$7.63
200 Day MA
$23.66
Beta
3.33
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/23/2026 | $0.03 | $0.28 | $0.03 | $0.28 | $2.80 | 267,731 |
| 10/22/2026 | $0.29 | $0.30 | $0.27 | $0.27 | $0.27 | 209,009 |
| 10/21/2026 | $0.31 | $0.32 | $0.31 | $0.32 | $0.32 | 58,600 |
| 10/20/2026 | $0.31 | $0.33 | $0.31 | $0.32 | $0.32 | 111,112 |
| 10/19/2026 | $0.32 | $0.33 | $0.31 | $0.32 | $0.32 | 192,086 |
| 10/16/2026 | $0.35 | $0.40 | $0.33 | $0.34 | $0.34 | 2,036,000 |
| 10/15/2026 | $0.36 | $0.37 | $0.33 | $0.34 | $0.34 | 165,118 |
| 10/14/2026 | $0.43 | $0.46 | $0.36 | $0.37 | $0.37 | 827,535 |
| 10/13/2026 | $0.43 | $0.44 | $0.41 | $0.41 | $0.41 | 332,165 |
| 10/12/2026 | $0.49 | $0.49 | $0.42 | $0.44 | $0.44 | 193,583 |
Analyst Price Targets
Based on analyst covering PPCB · as of Sep 17, 2026
Wall Street analysts forecast PPCB stock price to rise 442.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
US$1.52
+442.9% Upside
Current Price
US$0.28
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PPCB's historical volatility
30-Day Vol
693.7%
Annualized
90-Day Vol
438.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$3.35
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$2.97 | US$0.27 – US$32.54 |
| 60 trading days | US$3.15 | US$0.11 – US$93.09 |
| 90 trading days | US$3.35 | US$0.05 – US$211.40 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertake research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-18.18M
- Profit Margin
- 0.00%
- ROE (TTM)
- -161.86%
- EPS (Diluted)
- -176.20
- Book Value
- 2.84
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About PPCB.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| SBFM | Sunshine Biopharma Inc | $3.00 | +1696.41% |
| HCTI | Healthcare Triangle Inc | $6.71 | +1672.79% |
| BDRX | Biodexa Pharmaceticals | $3.39 | +717.97% |
| NVNWF | Nvni Group Limited | $0.00 | +193.75% |
| RITRF | Reitar Logtech Holdings Limited | $0.03 | +78.57% |
| CLRO | ClearOne Inc | $3.25 | +69.27% |
| BOLT | Bolt Biotherapeutics | $6.27 | +49.64% |
| ESLA | Estrella Immunopharma Inc. | $0.98 | +35.53% |